Are Breast Cancer Survivors at Risk for Developing Other Cancers?

  • Jaime S. Raymond
  • Carol J. Rowland Hogue
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 1)

Summary

Second primary cancers occur in ∼ 12% of women with an initial breast cancer diagnosis. This study assessed predictors of the risk of developing a second primary cancer after breast cancer. The analysis included 335,191 females, registered in the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database, who had been diagnosed with breast cancer. Observed numbers of subsequent cancers in the SEER database with a first breast cancer diagnosed from 1973 to 2000 were compared with the expected numbers based on age-adjusted incidence rates to calculate standardized incidence ratios. Kaplan-Meier curves were conducted to determine the median time until the second primary cancer diagnosis.

Average number of years until diagnosis varied by site and by age as well as median years until second cancer diagnosis. Most cancer risks decreased with age, but there was an increase in aging-related cancers such as lung cancer. The median years of follow-up were well beyond the 5-year mark. Breast cancer survivors should be advised of their increased risk for developing certain cancers in their lifetime.

Keywords

Estrogen Leukemia Oncol Sarcoma Rosen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society 2004. Available at http:// www.cancer.org/ Accessed January 9, 2004Google Scholar
  2. Bergfeldt, K., Silversward, C., Einhorn, S., and Hall, P. 2000. Overestimated risk of second primary malignancies in ovarian cancer patients. Eur. J. Cancer 36: 100–105PubMedCrossRefGoogle Scholar
  3. Bernstein, J.L., Lapinski, R., Lynch, C., Holford, T., and Thompson, W.D. 2002. Factors influencing mortality among young women with second primary breast carcinoma. Cancer 95(10): 2051–2058PubMedCrossRefGoogle Scholar
  4. Berstein, J.L., Lapinski, R.H., Takore, S.S., Doucette, J.T., and Thompson, W.D. 2003. The descriptive epidemiology of second primary breast cancer. Epidemiology 14(5): 552–558CrossRefGoogle Scholar
  5. Chu, K.U., Turner, R.R., Hansen, N.M., Brennan, M.B., Bilchik, A., and Giuliano, A.E. 1999. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann. Surg. 229(4): 536–541PubMedCrossRefGoogle Scholar
  6. Cimprich, B., Ronis, D.L., and Martinez-Ramos, G. 2002. Age at diagnosis and quality of life in breast cancer survivors. Cancer Pract. 10(2): 85–93PubMedCrossRefGoogle Scholar
  7. Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., and Goldgar, D.E. 1994. Risks of cancer in BRCA1 mutation carriers. Lancet 343: 692–695PubMedCrossRefGoogle Scholar
  8. Fritz, A., and Ries, L. (Eds). 1998. SEER Program Code Manual, 3rd edition. Bethesda, MD: National Cancer InstituteGoogle Scholar
  9. Howe, H.L., Weinstein, R., Hotes, J., Kohler, B., Roffers, S.D., and Goodman M.T. 2003. Multiple Primary Cancers of the Ovary in the United States, 1992–1997. Supplement to Cancer. Jones, V.E., and Raghavan, D. 1993. Quantum leaps in treatment of high-risk breast cancer? Prove it! Eur. J. Cancer 10: 1488–1493Google Scholar
  10. Kaplan, E.L., and Meier, P. 1958. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53: 457–481CrossRefGoogle Scholar
  11. Lee, E.T. 1980. Statistical methods for survival analysis. Belmont, CA: Lifetime Learning PublicationsGoogle Scholar
  12. Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F. Jr., Nelson, C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., and Tainsky, M.A. 1990. Germ line p53 mutations in a familial syndrome of breast cancer sarcomas, and other neoplasms. Science 250: 1233–1238PubMedCrossRefGoogle Scholar
  13. Matesich S.M., and Shapiro C.L. 2003. Second cancers after breast cancer treatment. Semin. Oncol. 30(6): 740–748PubMedCrossRefGoogle Scholar
  14. Percy, C., Van Holten, V., and Muir, C. (Eds). 1990. International Classification of Disease for Oncology, 2nd edition 1990 Geneva: World Health OrganizationGoogle Scholar
  15. Rauscher, G.H., Sandler, D.P., Poole, C., Pankow, J., Mitchell, B., Bloomfield, C.D., and Olshan, A.F. 2002. Family history of cancer and incidence of acute leukemia in adults. Am. J. Epidemiol. 156(6): 517–526PubMedCrossRefGoogle Scholar
  16. Ries, L.A.B., Eisner, M.P., Kosary, C.L., Hankey, B.F., Miller, B.A., and Clegg, L. 2003. SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer InstituteGoogle Scholar
  17. Rosen, P.R., Goshen, S., Saigo, P.E., Kinne, D.W., and Hellman, S. 1989. A long-term follow-up study of survival in stage I (T1N0M0) breast carcinoma. J. Clin. Oncol. 7: 355–366PubMedGoogle Scholar
  18. Roychoudhuri, R., Evans, H., Robinson, D., and Moller H. 2004. Radiation-induced malignancies following radiotherapy for breast cancer. Br. J. Cancer 91(5): 868–872PubMedGoogle Scholar
  19. Rubino, C., de Vathaire, F., Shamsaldin, A., Labbe, M., and Le, M.G. 2003. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. B r. J. Cancer 89(5): 840–846CrossRefGoogle Scholar
  20. Snedecor, G.W., and Cochran, W.G. 1980. Statistical Methods, 7th edition. Ames, IA: The Iowa State University PressGoogle Scholar
  21. Surveillance Research Program, National Cancer Institute SEER*Stat software 2004. (http://www. seer.cancer.gov/seerstat) version 5.0Google Scholar
  22. STATA Corporation 2002. STATA Statistics/Data Analysis, Version 7.0.Google Scholar
  23. Szabo, C.I., and King, M.C. 1997. Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet. 60: 1013–1020PubMedGoogle Scholar
  24. Turner, B.C., Harrold, E., Matloff, E., Smith, T., Gumbs, A.A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P.M., Thomas, A., and Haffy, B.G. 1999. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J. Clin. Oncol. 17: 3017–3024PubMedGoogle Scholar
  25. Yap, J., Chuba, P.J., Thomas, R., Aref, A., Lucas, D., Severson, R.K., and Hamre, M. 2002. Sarcoma as a second malignancy after treatment for breast cancer. Int. J. Rad. Oncol. Biol. Physics 52(5): 1231–1237CrossRefGoogle Scholar
  26. Young, J.L. Jr., Roffers, S.D., Ries, L.A.G., Fritz, A.G., and Hurlbut, A.A. (Eds). 2001. SEER Summary Staging Manual — 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute, NIH Pub. No. 01–4969Google Scholar

Copyright information

© Springer Science + Business Media B.V. 2008

Authors and Affiliations

  • Jaime S. Raymond
    • 1
  • Carol J. Rowland Hogue
    • 1
  1. 1.Rollins School of Public HealthEmory UniversityAtlanta

Personalised recommendations